You are here: Industry Insights > Aurinia

News List

Aurinia reports favourable assessment of LUPKYNIS in ICER pharmaceutical-technology
March 18, 2021
Aurinia Pharmaceuticals (IPHAF) has announced a positive cost-effectiveness assessment of LUPKYNIS (voclosporin) based on the Institute for Clinical and Economic Review (ICER) revised evidence report analysis.
Catalent, Aurinia Ink LUPKYNIS Commercial Supply Pact contractpharma
February 20, 2021
Catalent has signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals for LUPKYNIS (voclosporin), a drug to treat adult patients with lupus nephritis (LN).
Aurinia and Lonza Expand Manufacturing Partnership contractpharma
December 17, 2020
Aurinia Pharmaceuticals and Lonza have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonza’s existing small molecule API facility in Visp ...
Aurinia begins voclosporin trial in kidney transplant recipients with Covid-19 pharmaceutical-business-review
October 30, 2020
Aurinia Pharmaceuticals has announced the commencement of an open-label exploratory trial to assess antiviral activity of voclosporin in kidney transplant recipients (KTRs) with Covid-19.
Aurinia Pharmaceuticals: Where to From Here? fool
April 01, 2017
March has proven to be a rollercoaster ride for shareholders of Aurinia Pharmaceuticals (NASDAQ:AUPH), with shares climbing almost 200% at one point before pulling back.